Navigation Links
FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
Date:10/14/2011

SILVER SPRING, Md., Oct. 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Ferriprox (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Patients with thalassemia have excess iron in the body from the frequent blood transfusions (transfusional iron overload), a condition that is serious and can be fatal.  These patients also have a risk of developing liver disease, diabetes, arthritis, heart failure or an abnormal heart rhythm.  

The standard of care to treat transfusional iron overload is chelation therapy – chemical agents that are used to remove heavy metals from the body. Ferriprox is intended for use when chelation therapy is inadequate.

"Ferriprox represents the first new FDA-approved treatment for this disorder since 2005," said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.

The safety and effectiveness of Ferriprox is based on an analysis of data from twelve clinical studies in 236 patients. Patients participating in the study did not respond to prior iron chelation therapy.  Ferriprox was considered a successful treatment for patients who experienced at least a 20 percent decrease in serum ferritin, a protein that stores iron in the body for later use. Half of the patients in the study experienced at least a 20 percent decrease in ferritin levels.

The most common side effects seen in patients who received Ferriprox included nausea, vomiting, abdominal and joint pain, urine discoloration (chromaturia), a decrease in the number of white blood cells (neutropenia), and an increase in
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 /PRNewswire/ ... has recently added DrugPatentWatch to its ... http://www.bharatbook.com/drugpatentwatch-tour.pdf )      (Logo: ... comprehensive information on pharmaceutical, drug patents ... supports the critical business functions of ...
(Date:6/19/2013)... , June 19, 2013 DST Health ... and services to health plans, integrated delivery systems, and ... Medical Drug Management Service (MDMS) has jumped ... edit and automate the pricing of medical prescription drug ... efficiencies by automating their medical drug claims processes. As ...
(Date:6/19/2013)... 2013   Life Technologies Corporation (NASDAQ: ... granting Suzhou Ribo Life Sciences (Ribo) the exclusive ... China using Life,s Invivofectamine® ... molecules in combination with Invivofectamine® Rx to create ... with high unmet medical need in the Chinese ...
Breaking Medicine Technology:Drug Patent Watch 2Drug Patent Watch 3Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 2Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4
... Bioness Inc., today announced the commercial release of its ... Drug Administration (FDA) earlier this year, the L300 Plus combines ... thigh cuff to activate even more of the nerves and ... The L300 Plus is intended for people ...
... LLC , a drug research and development company focused ... its compound CM-182 demonstrated positive results for reduction in ... screening was performed by the contract research organization, Cerca ... C57BL/6 mice exhibited a dose dependent reduction in hyperactivity ...
Cached Medicine Technology:Bioness Inc Announces Availability of L300 Plus System 2Curemark Reports Positive Results for Novel Compound CM-182 in Amphetamine Induced Hyperactivity 2
(Date:6/20/2013)... Millions of Britons are risking ... because they do not brush their teeth every day, ... , Seven million Britons do not clean their teeth ... latest data from the British Dental Health Foundation shows. ... the BDHF also admitted that they forgot to floss ...
(Date:6/20/2013)... In an article found on Science ... can show similarities between an addiction to drugs, and ... current global obesity pandemic. , To test the hypothesis ... one can be addicted to drugs, Dr Francesco Leri, ... the University of Guelph, has studied the effects of ...
(Date:6/20/2013)... 20, 2013 Creighton University ... Service Honor Roll – the highest federal recognition a ... volunteering, student- service learning and civic engagement as well ... the Corporation for National and Community Service, is given ... Creighton. “Our foundation at Creighton is based on spiritual ...
(Date:6/19/2013)... (PRWEB) June 20, 2013 Everyone is looking for ... and inexpensive way to do so. It is called Skin ... - only 5 minutes per day - to improve health and ... improves general health. How? , Skin Brushing improves general health ... it aids the lymphatic system to drain toxins , ...
(Date:6/19/2013)... (PRWEB) June 20, 2013 Shreya Rangarajan ... the global youth summit on the future of medicine. ... to the Global Youth Summit on the Future of ... Park Country School and the state of Maryland at ... providers will practice in an environment hard to imagine ...
Breaking Medicine News(10 mins):Health News:Millions Are Risking Gum Disease, Warn Eludril And Elgydium 2Health News:Millions Are Risking Gum Disease, Warn Eludril And Elgydium 3Health News:Research Suggests That Unhealthy Food Addiction Could Explain Global Obesity Epidemic 2Health News:Creighton Again Named to President’s Honor Roll - University Picks Up Sixth Recognition Award for Service 2Health News:Creighton Again Named to President’s Honor Roll - University Picks Up Sixth Recognition Award for Service 3Health News:A Fast and Fun Way to Better Skin Quality and Overall Health, says Sublime Beauty® 2Health News:Global Youth Summit on The Future of Medicine-Shreya Rangarajan selected to represent Roland Park Country School and The State of Maryland 2Health News:Global Youth Summit on The Future of Medicine-Shreya Rangarajan selected to represent Roland Park Country School and The State of Maryland 3
... the U.S. Food,and Drug Administration (FDA) approved Abbott,s TRILIPIX(TM) ... help lower triglycerides,and LDL cholesterol, and to raise HDL ... first and only fibrate to be approved for use ... guidelines,recommend the combination of a fibrate with a statin ...
... 15 Two leading cancer physicians and,researchers affiliated with ... Antonio Breast Cancer Symposium. Three others presented their,research in ... 14. , Dr. ... its breast,cancer research committee, presented findings on the largest ...
... role in immune, inflammatory processes, study says , , ... have higher levels of the obesity-related hormone leptin than ... study included 77 psoriasis patients and a control group ... researchers gathered health information about the participants and analyzed ...
... to Controlling Costs, Improving Quality as Health Care Reform Debate Centers ... WASHINGTON, Dec. 15 House Ways and Means Health Subcommittee Chairman ... senior counsel to Sen. Max Baucus, will join health care expert ... America,s Future co-director Roger Hickey on a conference call ...
... first piece of DNA luxury jewellery will be sold,at ... be used to finance the,anti-aging services and life extension ... Dr. Ivan de Weber, a ... co-founder of both Inneova(TM) and DNArtistic has,brought together a ...
... High School Student Volunteers Collaborate in Musical Production , ... HAWTHORNE, N.J., Dec. 15 Sharing The ... organization and conservatory bringing together individuals with mild to ... to announce that its members, all children and teens ...
Cached Medicine News:Health News:Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 2Health News:Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 3Health News:Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 4Health News:US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium 2Health News:US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium 3Health News:US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium 4Health News:Obesity-Related Hormone Tied to Psoriasis 2Health News:DNA Jewel to Finance Anti-Aging Services & Cancer Research 2Health News:Sharing The Arts & Ridgewood High School Present Musical Production of Charlie and The Chocolate Factory 2
Key periosteal elevators, blade width 1" (25 mm), total length 7 1/2" (191 mm)....
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Cushing periosteal elevators, Gutsch handle, sharp, narrow, blade width 3/16" (5 mm), length 7 5/8" (194 mm)....
Cushing Little Joker periosteal elevators, solid handle, blade width 1/4" (6 mm), length 7 1/2" (191 mm)....
Medicine Products: